ORGANISATION/COMPANYFUNDACIÓN PROGRESO Y SALUD
RESEARCH FIELDBiological sciences
RESEARCHER PROFILERecognised Researcher (R2)
APPLICATION DEADLINE22/06/2018 23:00 - Europe/Brussels
LOCATIONSpain › Granada
TYPE OF CONTRACTOther
HOURS PER WEEK40
EU RESEARCH FRAMEWORK PROGRAMMEH2020
The group “Gene Regulation, Stem cells and Development” lead by Dr. Verónica Ramos-Mejía at the Centre for Genomics and Oncological Research (GENYO) in Granada (Spain) is interested in hosting a Marie Curie Fellowship.
Dra. Ramos-Mejia’s group is developing new cellular and computational models of pediatric AML, aiming to understand the molecular pathways that are altered and identify new therapeutic targets.
The Marie Curie Project will aim to generate and validate iPSC-based cellular models of pediatric AML as new clinically relevant models for preclinical studies. Hence, Dra. Ramos-Mejia’s is interested in supporting a fellow with strong background in leukemia biology and experience on human pluripotent cell culture systems and associated functional, molecular and bioinformatic analyses.
Marie Curie Post Doc position at the Centre for Genomics and Oncological Research (GENYO) (Granada, Spain)
Description of the center:
The Centre for Genomic and Oncology Research (GENYO) Pfizer-Universidad de Granada-Junta de Andalucía, is a mixed research centre funded by the Department of Equality, Health and Social Politics, the Department of Economy, Innovation, Science and Employment, the University of Granada and the pharmaceutical company Pfizer. The institute is designed as an excellence research space to investigate the genetic basis of diseases, including cancer, and the influence of inheritance in the host response to certain drugs. GENyO is the first centre in Spain dedicated to genomic research, which integrates Public Administration, the University and biotechnology and pharmaceutical companies. Thus, GENyO will facilitate research in all its phases and it has been designed with the aim to become an international reference centre to develop excellence research in genomics applied to health.
Description of the group:
Human pluripotent stem cells (hPSCs) have an unlimited proliferation capacity as well as the potential to differentiate to any cellular type present in the adult. We use hPSCs as a cell model to study the molecular mechanisms regulating hematopoietic and endothelial development in humans, optimize differentiation protocols towards these cell lineages, and apply this knowledge to the generation of disease models.
Acute Myeloid Leukemia (AML) is the cancer with the highest mortality rate among children, even though it is considered a rare disease. In adults, AML arises after the accumulation of somatic mutations in hematopoietic progenitors, while in children; AML is caused by chromosomal alterations that occur in utero. At the moment, children affected with AML are treated with the same drugs as adults, even though the origin of the transformation events and the prognosis are different.
Our group is developing new cellular and computational models of pediatric AML, aiming to understand the molecular pathways that are altered and identify new therapeutic targets.
Description of the project/projects:
Acute Myeloid Leukemia (AML) is a rare disease, biologically and genetically very heterogeneous, that is becoming the leading cause of pediatric leukemic mortality. Nowadays, up to 50% of children with AML die because of the disease or due to treatment-related complications. It is not possible to improve prognosis by simply increasing chemotherapy, as current cytotoxic therapies come with a severe cost to the health of patients, often resulting in treatment-related death or long term sequels such as cardiac damage. Therefore, it is capital to generate adequate models to develop new therapeutic approaches that will improve outcomes for children with AML.
Here, we will develop cellular and computational models that recapitulate the genotypic heterogeneity of pediatric AML. As there is now compelling evidence that the initiating molecular events in pediatric leukemia occur during fetal development, we will generate induced pluripotent stem cell (iPSC)-based cellular models of pediatric AML, through the reprogramming of fully characterized leukemic cells from patients of different subtypes. We will also generate computational models based on the integration of the mutational profiling of pediatric AML patients, to identify core biological pathway with potential therapeutic intervention.
Then, using our own iPSC-based cellular models of pediatric AML we will determine the relevance of the selected signaling pathways in the leukemic phenotype, and we will test the efficacy of the predicted therapies. Our final goal is to use these tools as preclinical models and in this way find specific treatments for the different pediatric AML subtypes.
• Project 1 Objective: To generate and validate iPSC-based cellular models of pediatric AML as new clinically relevant models for preclinical studies
• Project 2 Objective: To integrate genomic data of pediatric AML for the generation of a gene signature model as a predictive tool for clinical outcome and define potential compounds, biomarkers and targets.
Description Principal Investigator:
Dr. Ramos-Mejía is an expert in human pluripotent stem cell (hPSC) biology and human hematopoietic development. Her main interest is to investigate pediatric acute myeloid leukemias (AML) and the generation of novel tools to find specific treatments for the different pediatric AML subtypes.
ORCID ID: 0000-0002-8013-4273
Researcher ID : 0000-0002-8013-4273
Publications= 42 H Index=18 Patent=2 Grants=2
Supervisor International collaborations:
• Pediatric leukemia Mexico City Network
Supervisor most relevant research projects grants:
• Integral study of pediatric leukemia
• Developing new models to study pediatric leukemia
REQUIRED EDUCATION LEVELBiological sciences: PhD or equivalent
• Skills: strong background in leukemia biology and standard molecular and cell biology techniques.
• Specific requirements: experience on human pluripotent cell culture systems and associated functional, molecular and bioinformatic analyses. Academic skills, good collaboration skills and ability to work independently.
• Degree: doctoral degree or have at least four years of full-time equivalent research experience.
• Degree field: PhD in the fields of biochemistry, biology, biomedicine, medicine or similar.
• Main research field: Stem cell biology.
• Sub research field: Leukemia.
• Years of research experience: 3.
Interested applicants should send their CV, the contact information of two referees and a motivation letter.
Deadline: 8th June 2018.
EURAXESS offer ID: 298649